ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ADPT Adaptive Biotechnologies Corporation

3.45
0.00 (0.00%)
Pre Market
Last Updated: 09:00:01
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adaptive Biotechnologies Corporation NASDAQ:ADPT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.45 3.35 4.20 0 09:00:01

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

24/05/2023 9:05pm

GlobeNewswire Inc.


Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart


From Jun 2022 to Jun 2024

Click Here for more Adaptive Biotechnologies Charts.

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

  • William Blair 43rd Annual Growth Stock Conference in Chicago, ILPresenting on Wednesday, June 7th at 8:40 a.m. Central Time
  • Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CAFireside chat on Monday, June 12th at 4:00 p.m. Pacific Time

Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@adaptivebiotech.com

ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations201-396-1687investors@adaptivebiotech.com

1 Year Adaptive Biotechnologies Chart

1 Year Adaptive Biotechnologies Chart

1 Month Adaptive Biotechnologies Chart

1 Month Adaptive Biotechnologies Chart